{"id":"W3124162597","doi":"10.1002/cncr.33378","title":"Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Pembrolizumab; Medicine; Glioblastoma; Oncology; Programmed cell death 1; Internal medicine; Cancer research; Cancer; Immunotherapy; PD-L1","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003074884,0.001297417,0.001109715,0.0003456477,0.0003184722,0.0009487764,0.0006265601,0.0008953584,0.001979838],"category_scores_gemma":[0.001386149,0.000321538,0.001337234,0.0003435095,0.0004443149,0.0009504026,0.0003859418,0.001697413,0.0004410112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000853316,"about_ca_system_score_gemma":0.0007595355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006986673,"about_ca_topic_score_gemma":0.002043463,"domain_scores_codex":[0.9993106,0.0003922091,0.00004026873,0.0001024774,0.00006652634,0.0000880019],"domain_scores_gemma":[0.999185,0.000146164,0.0002949657,0.00008262073,0.00007136317,0.0002199334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7809912,0.01460144,0.01365766,0.002085458,0.007039479,0.0002282587,0.000392931,0.002871068,0.01699221,0.0003960515,0.009904192,0.1508399],"study_design_scores_gemma":[0.7504211,0.1849633,0.04456552,0.0002836127,0.004568694,0.0007774757,0.0001898778,0.00189756,0.003674078,0.0007478098,0.007825172,0.0000857593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891589,0.006918236,0.0003418391,0.0005456325,0.00008897221,0.0006863837,0.001176522,0.00005767957,0.001025593],"genre_scores_gemma":[0.9886653,0.003681211,0.001076219,0.001088534,0.0001662148,0.001068438,0.002922014,0.00002996608,0.001302071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003074884,"threshold_uncertainty_score":0.01626176,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03357872649936543,"score_gpt":0.3363036082193984,"score_spread":0.302724881720033,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}